The pharmaceutical company's executives changed frequently, and 21 people left during the year!

【Pharmaceutical Network Industry News】Under the change of the pharmaceutical environment, the change of senior management of pharmaceutical companies is also accelerating
.
Flush data shows that since 2022, a total of 1,401 executives in the A-share biomedical industry have left, involving 357 companies, which are mainly concentrated in chemical drugs, traditional Chinese medicine, APIs and other industries
.
Some enterprises had a large number of employees during the year, with 19 companies with more than 10 employees and 91 companies with 5-10 employees
.
Among them, the senior management of Unnamed Pharmaceutical has changed frequently this year, with 21 people leaving during the year, in addition to 11 directors, there are 10 people including chairman, general manager, deputy general manager and other positions
.
For example, not long ago, some media reported that Unnamed Pharmaceutical issued an announcement that Pan Aihua, the company's founder and chairman, officially stepped down, and Yue Jialin became the company's chairman
.
On May 31, Unnamed Pharmaceutical announced that the company's board of directors recently received the resignation report submitted by Mr.
Li Yan, the company's deputy general manager, and Mr.
Li Wei applied to resign as the company's deputy general manager due to personal reasons, and Mr.
Li Wei will no longer hold any position
in the company after his resignation.
On April 11, the company announced that Ms
.
Xu Ruoran applied to resign as the company's co-general manager due to personal reasons.
Mr.
Shi Xuezhong, Deputy General Manager of the Company, will no longer act as the secretary of the Board of Directors; Mr.
Li Yan, the deputy general manager of the company, is no longer concurrently the chief financial officer
.
Mr.
Shi Xuezhong and Mr.
Li Yan remain the deputy general managers of
the Company.
At the same time, the board of directors of the company agreed to appoint Mr.
Yue Jialin as the joint general manager of the company; Mr.
Zhao Hui is the secretary of the board of directors of the Company; Mr.
Zhou Bin is the Chief Financial Officer
of the Company.
According to the data, Wuming Pharmaceutical is a company mainly engaged in pharmaceutical manufacturing and CDMO biomedical research and development, and its business segments include nerve growth factor plate, interferon plate, vaccine plate, biomedical CRO/CDMO plate, forest ginseng plate and pharmaceutical intermediate plate
。 According to the third quarter report of 2022, the company achieved main revenue of 276 million yuan, a year-on-year decrease of 12.
75%; the net profit attributable to the parent was 64.
4504 million yuan, down 81.
45% from the same period last year; deducted non-net profit of 60.
1606 million yuan, down 82.
36% from the same period last year; Among them, in the third quarter of 2022, the company's main revenue in a single quarter was 87.
8841 million yuan, a year-on-year decrease of 3.
92%; The net profit attributable to the parent in a single quarter was 40.
4938 million yuan, down 80.
67% from the same period last year; The non-net profit in a single quarter was 41.
5062 million yuan, down 80.
15%
from the same period last year.
Since the beginning of this year, in addition to Unnamed Pharmaceutical, there have been news of the departure of important executives such as chairmen, general managers, and deputy general managers of many pharmaceutical companies
.
For example, on November 16, YaoTesco announced that the company recently received a written resignation report
submitted by Hao Ruizhi, secretary of the company's board of directors and deputy general manager.
Hao Ruizhi applied to resign as the secretary of the board of directors and deputy general manager of the company due to personal reasons
.
On November 2, Cylon Pharmaceutical announced that Mr.
Tong Yan applied to resign as the deputy general manager of the company due to personal reasons, and after his resignation, Mr.
Tong Yan will not hold any position
in the company and its subsidiaries.
On November 1, Thalys Medical issued an announcement that Mr.
Liu Feng, the company's deputy general manager, resigned as the company's deputy general manager due to personal reasons
.
On October 20, Wise Pharma issued an announcement that Mr.
Hua Fengmao resigned from the company's director, CEO, special committee of the board of directors and relevant positions in subsidiaries due to personal reasons, and will no longer hold any position
in the company and its subsidiaries after his resignation.
The industry believes that in recent years, the pharmaceutical industry has been affected by policies such as the normalization of centralized procurement and consistency evaluation, and corporate profits have been under pressure, and it is necessary to accelerate transformation and upgrading, and the accompanying personnel changes will be more frequent
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.